ReviewDrug design, development and therapy2026
Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential.
Mariam Alamgir et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.